A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

2014-07-23 21:35:10 | BioPortfolio


Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.


Hypothesis to be tested:

Infectious corneal ulceration causes corneal scarring, opacification, and blindness in hundreds of thousands of children annually. In developing countries, it is the number one cause of avoidable blindness in children. While in some cases, the cornea was healthy prior to ulceration, in others; xerophthalmia, trachoma, rubeola, trauma, or some other cause previously compromised the cornea. Even when the ulceration is associated with one of the above etiologies, it is usually the bacterial corneal ulcer that directly leads to blindness in the short-term. In many countries, few of these infections are properly treated with appropriate antimicrobial agents due to a number of factors, including cost, availability, and effectiveness. If a topical antimicrobial agent were readily available in developing countries which is also inexpensive and effective, many of these ulcers could be cured before scarring and blindness result.

The best candidate for such a medication is povidone-iodine ophthalmic solution. It has already been proven the best agent to sterilize the ocular surface before and after eye surgery and to prevent conjunctivitis in newborn babies. It was also shown an effective treatment against bacterial conjunctivitis in children. Povidone-iodine ophthalmic solution can be prepared in a local hospital or clinic by mixing the powder with an ophthalmic saline solution bringing the cost of a 10-ml bottle to less than US $0.10. By contrast, in the Philippines, a 10 ml. bottle of Neosporin ophthalmic solution cost about $4.00 and it may take a few bottles to cure a bacterial corneal ulcer. For far less than a U.S. dollar, a corneal ulcer could be fully cured. Povidone-iodine has the widest antimicrobial spectrum of any known topical medication. It has been shown to be effective against all bacteria, fungi, and viruses. No true resistance to povidone-iodine has ever been demonstrated. Allergic reactions are rare. Thus, if any medication could serve the purpose for this study, it would be povidone-iodine.

The primary research question is whether povidone-iodine ophthalmic solution is effective in healing bacterial corneal ulcers, which, if proven, would have a dramatic effect in reducing pediatric blindness.

The number of subjects was determined from the primary outcome measure of non-inferiority to achieve a minimum of a one-day difference between the control and investigative groups, with povidone-iodine being compared to the control medication at each study site. The control medications are Neosporin ophthalmic solution in Manila and ciprofloxacin ophthalmic solution in the two combined Indian sites (Hyderabad and Tiruchirapalli) for a total of four study arms. The number of recruits was calculated to achieve 90% power for detecting non-inferiority using t-tests with a level of significance of 0.05 for comparing mean time to cure. Cure is defined as closure of the epithelial defect with no inflammatory signs other than minimal injection.

Subjects provided written consent. As appropriate, child assent was also obtained. At each study site, subjects were allocated to receive either povidone-iodine or the control medication. If corneal ulcers were present bilaterally, one eye was randomized to receive povidone-iodine, while the other received the control medication standard for that center. All subjects were hospitalized for at least 7 days for careful monitoring and appropriate treatment. To assure compliance, all subjects had their medications administered by medical personnel.


The study medication is 1.25% povidone-iodine and the control medications are Neosporin ophthalmic solution in Manila, Philippines and ciprofloxacin 0.3% ophthalmic solution in Hyderabad and Tiruchirapalli, India. These medications are the standard of care at each respective study site. The only eye medication permitted beside povidone-iodine 1.25% ophthalmic solution and the control medications (Neosporin and ciprofloxacin) is atropine ophthalmic solution to reduce intraocular inflammation and prevent synechiae. The atropine solution is administered to the affected eye(s) twice a day. Subjects less than one year old receive a 0.25% solution, those aged one to three years receive 0.5%, and those older than 3 years receive the 1% solution.

The dosing schedule of povidone-iodine 1.25% or control ophthalmic solutions is as follows:

1. For the first three days, one drop of the medication is applied every hour.

2. Day 4 and thereafter: hourly while awake. When asleep (sleep not to exceed 9 hours), drops are administered every three hours. All cases are treated with this intense drop therapy for a minimum of 5 days unless criteria for change in therapy are met (see below).

3. At 5 days: If there is no deterioration in any factor (see below) and improvement in at least one factor (other than epithelial defect size) on 2 consecutive examinations, dosing frequency is decreased to every 2 hours while awake (about 8 times/day) for 2 days, then 4 times/day until discharge. If status remained unchanged at Day 5, intense drop therapy continues for 5 more days.

4. If at 10 days the status is unchanged, the subject exits the study.

All patients are examined daily and have their visual acuity and ocular examination documented. The daily eye examination findings are scored and recorded for the following six factors:

1. Visual acuity

2. Inflammatory signs

3. Stromal infiltrate dimensions

4. Epithelial defect dimensions


6. Tissue firmness, including keratic precipitate (KP),anterior chamber(AC)cellular reaction, AC fibrin and hypopyon status.

The daily assessment of the ulcer status is classified as cured, improved, persistent, worsening or failure.

Criteria for Change in Therapy:

Within the first 48 hours, treatment is changed for deterioration in all factors or appearance of a descemetocele. After 48 hours of treatment, treatment is changed for deterioration in one or more of the following factors on 2 consecutive examinations: stromal infiltrate, melt, or two or more signs or symptoms of inflammation. Epithelial defect size is used only for assessing status; not for change in medication. The new treatment is left to the discretion of the ophthalmologist.

Culture Technique:

All subjects undergo microbiological analysis of the corneal ulcer upon intake into the study. A spatula is applied to the cornea of the affected eye(s) and blood agar and chocolate agar plates and brain heart infusion broth (BHI) are streaked for each patient. Cultures are repeated daily until two negative cultures are obtained. If the cultures are positive for any organism, that organism is considered the infecting agent. Each culture plate is incubated for at least seven days and the colony forming units are differentiated and enumerated by standard bacteriological techniques, including the VPI technique for anaerobic bacteria. No culture growth at seven days constitutes a negative culture.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Infected Corneal Ulcers




Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
United States




University of California, Los Angeles

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:35:10-0400

Clinical Trials [1215 Associated Clinical Trials listed on BioPortfolio]

Nasal Swab studyComparison of Effectiveness of Povidone-iodine Versus Saline Versus 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP Swabs for Decolonizing Intranasal MSSA/MRSA

To determine if routinely available 10% povidone-iodine swabs are more effective than saline and 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP for decolonizing MRSA.

Povidone-Iodine Against Sodium Hypochlorite as Skin Antiseptics

The investigators have few options for skin antisepsis. Alternatives for povidone-iodine, which is the most commonly used agent, are costly or ineffective. To have more options, this study...

Povidone-iodine Versus Saline in Vaginal Cleansing Before Office Hysteroscopy

The normal saline is used in medicine as an intravenous isotonic infusion and for cleaning wounds. It is a mild but effective cleaning agent and will not harm normal tissue, unlike many st...

Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine

The study has 2 groups. Group A in which the subcutaneous tissue will be swabbed with 10 cc of undiluted 10% povidone iodine and will not be mobbed. Group B ; No swabbing. Women in both gr...

Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery

Primary Hypothesis: chlorhexidine gluconate antiseptic vaginal preparation is superior to povidone-iodine vaginal preparation in decreasing the bacterial load within the vagina when preppi...

PubMed Articles [3424 Associated PubMed Articles listed on BioPortfolio]

Optimizing the antisepsis protocol: Effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0.

To determine the minimum effective concentration of povidone-iodine that reduces the bacterial load by 3-log10, the U.S. Food and Drug Administration requirement for antiseptic agents, and to study al...

Effect of Povidone Iodine 5% on the Cornea, Vision, and Subjective Comfort.

To determine the effects of povidone iodine 5% (Betadine 5%) applied to the eye on visual function, corneal integrity, and subjective complaints.

Application of povidone-iodine at delivery significantly increases maternal urinary iodine but not neonatal thyrotropin in an area with iodine sufficiency.

The aim of the present study was to investigate the effect of povidone-iodine (PVP-I) application at delivery on maternal urinary iodine concentration (UIC) and neonatal thyrotropin concentration.

Antisepsis of the skin before spinal surgery with povidone iodine-alcohol followed by chlorhexidine gluconate-alcohol versus povidone iodine-alcohol applied twice for the prevention of contamination of the wound by bacteria: a randomised controlled trial.

The aim of this study was to determine whether the sequential application of povidone iodine-alcohol (PVI) followed by chlorhexidine gluconate-alcohol (CHG) would reduce surgical wound contamination t...

Capsular bag irrigation using 0.025% povidone-iodine in balanced salt solution PLUS for the treatment of postoperative endophthalmitis.

We examined the effectiveness and adverse events of using balanced salt solution (BSS) PLUS containing 0.025% povidone-iodine, a non-oculotoxic concentration, for capsular bag irrigation in a case of ...

Medical and Biotech [MESH] Definitions

An iodinated polyvinyl polymer used as topical antiseptic in surgery and for skin and mucous membrane infections, also as aerosol. The iodine may be radiolabeled for research purposes.

Preparations used as alternatives or supplements to hand washing with soap and water to destroy microorganisms and prevent transmission of pathogens. The active ingredient may be ETHANOL; 1-PROPANOL; or POVIDONE-IODINE in a gel, foam, or liquid solution.

Stable iodine atoms that have the same atomic number as the element iodine, but differ in atomic weight. I-127 is the only naturally occurring stable iodine isotope.

A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140)

New blood vessels originating from the corneal veins and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.

More From BioPortfolio on "A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers"

Quick Search

Relevant Topics

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Searches Linking to this Trial